本文研究了监护室内患下呼吸道感染的危重病人体内Aztreonam(AZT)的药代动力学,并探讨了在肺部感染时,药物在支气管分泌物中是否达到有效浓度。选女性2名、男性8名,年龄18-77岁,所有病人均需气管插管。3人为支气管炎,7人为支气管肺炎。药物剂量范围15.7-36.4mg/kg,在研究过程中未用其它抗生素。在首次静注(3分钟)AZT 2克后,血清中平均浓度是242.6±140mg/L,在用药后8小时(第2次给药前)是4.4±3.3,尿浓度始终较高,且主要以原药排泄。在用药后2 This article investigates the pharmacokinetics of aztreonam (AZT) in critically ill patients with respiratory tract infections in intensive care units and explores whether drugs reach effective concentrations in bronchial secretions during lung infections. Female 2, male 8, aged 18-77 years, all patients need endotracheal intubation. 3 for bronchitis, 7 for bronchial pneumonia. The drug dose ranged from 15.7 to 36.4 mg / kg and no other antibiotics were used during the study. The mean serum concentration was 242.6 ± 140 mg / L after the first intravenous (3 min) 2 mg AZT, 4.4 ± 3.3 8 hrs after the second dosing (before dosing 2), urine concentrations were consistently high and predominantly To the original drug excretion. After treatment 2